Comparison 2. Anti‐leukaemic therapy with alemtuzumab versus anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical in both groups, confounded).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Treament related mortality	2	177	Risk Ratio (M‐H, Fixed, 95% CI)	3.20 [0.66, 15.50]
2 Treatment related mortality ‐ subgrouped by alemtuzumab treatment regiment	2	177	Risk Ratio (M‐H, Fixed, 95% CI)	3.20 [0.66, 15.50]
2.1 first‐line therapy	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	9.11 [0.50, 166.53]
2.2 relapse therapy	1	12	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.13, 8.00]
3 ORR ‐ overall analysis	2	170	Risk Ratio (M‐H, Fixed, 95% CI)	0.95 [0.85, 1.07]
4 ORR ‐ subgrouped by alemtuzumab treatment regimen	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 first‐line therapy	1	159	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.83, 1.04]
4.2 relapse therapy	1	11	Risk Ratio (M‐H, Fixed, 95% CI)	1.75 [0.63, 4.88]
5 CRR ‐ overall analysis	2	170	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.67, 1.08]
6 CRR ‐ subgrouped by alemtuzumab treatment regimens	2	170	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.67, 1.08]
6.1 first‐line therapy	1	159	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.64, 1.03]
6.2 relapse therapy	1	11	Risk Ratio (M‐H, Fixed, 95% CI)	3.5 [0.45, 27.52]